1,066 results on '"Muscular Dystrophy, Facioscapulohumeral"'
Search Results
2. Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (FORTITUDE)
3. A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy (MANOEUVRE)
4. An 18-month Prospective Natural History Study to Gain Insight Into FSHD2 Pathophysiology and Disease Progression (INSIGHT FSHD2)
5. Development and Validation of the FBIndex to Determine the Risk of Falls for Patients with Neuromuscular Disorders (FBIndex)
6. The Risk of Falls Index for Patients With Neuromuscular Disorders
7. Walking ANalysis Interest in Persons with FacioscapulohumEral Muscular Dystrophies (WANTED)
8. A Registered Cohort Study on FSHD1
9. Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD (ReSolve)
10. Phase 2 Open-label Extension Study of AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD) (FORTITUDE-OLE)
11. Disease Burden and Living Situation of Patients With Facioscapulohumeral Muscular Dystrophy
12. Study to Evaluate the Efficacy and Safety of Satralizumab in FSHD1 (REINFORCE)
13. Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
14. Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy
15. Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) (FSHD)
16. Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study
17. Quantitative Assessment of Orofacial Muscle Function in FSHD
18. The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient Registry
19. Rehabilitation in Muscular Dystrophies From the Hospital Facility to the Home: Pilot Project [RIMUDI] (RIMUDI)
20. Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD) (MOVE FSHD)
21. At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
22. Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)
23. ADVANCED FSHD-COM: New Clinical Outcome Measures to Evaluate Non-ambulant FSHD Patients, a Pilot Study (ADVANCED)
24. New Clinical Outcome Measures to Remotely Evaluate Patients With FacioScapuloHumeral Muscular Dystrophy (PROGRESS-FSHD)
25. Magnetic Resonance Imaging and Ultrasound Comparison With Load Evaluation (MUSCLE+)
26. Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD) (FSHD)
27. Computerized Facial Recognition for Automated Diagnosis of the Facio-Scapulo-Humeral Muscular Dystrophy (FSMHD) (CV4DIAGNOSIS)
28. Pro-inflammatory Cytokines in Facioscapulohumeral Muscular Dystrophy (CYTOKINE-FSH) (CYTOKINE-FSH)
29. Clinical, Genetic and Epigenetic Characterization of Patients With FSHD Type 1 and FSHD Type 2
30. Neurological and Psychiatric Comorbidities Patients With FSHD 1 and 2
31. FSHD Molecular Characterization
32. Unraveling Metabolic Involvement in Facioscapulohumeral Dystrophy Through Metabolomics (METIN-FSHD)
33. Effectiveness of Upper Extremity Rehabilitation in pwFSHD (Patient With Facioscapulohumeral Dystrophia)
34. Longitudinal Study on Diaframmatic Ultrasound in FSHD Patients
35. Biomarker Development for Muscular Dystrophies
36. Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) (FSHD)
37. Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy (FSHD)
38. Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort
39. Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension
40. Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension (FSHD)
41. Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)
42. New Biomarkers in Facioscapulohumeral Muscular Dystrophy, Multispectral Optoacoustic Tomography. (MSOT-FSHD)
43. Study of Testosterone and rHGH in FSHD (STARFISH)
44. Effect of Creatine Monohydrate on Functional Muscle Strength in Children With FSHD
45. Understanding Control and Mechanisms of Shoulder Instability in FSHD
46. Examination of Operative Approach in pwFSHD (Patient With Facioscapulohumeral Muscular Dystrophy)
47. Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)
48. Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)
49. Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders
50. Digital Biotyping of FSHD Patients and Controls
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.